Synaptogenix, Inc. (SNPX) - צמיחת רווח נקי למניה אחת לשנה הנוכחית

The development of neuromedicine relies on the strict transportation of biomaterials with temperature control. The distribution of the annual change in earnings per share demonstrates current volatility, where 0.00 captures the magnitude of this parameter. However, the lack of revenue and a cash deficit due to testing costs create delisting risks, making investments in Synaptogenix, Inc. (SNPX) dependent on the outcome of future clinical trials.

This indicator measures the dynamics of earnings per share, reflecting the growth or contraction rates of business profitability relative to the previous year. By analyzing the year-over-year EPS comparison, an investor determines capital management efficiency and the company's valuation potential. For Synaptogenix, Inc. (SNPX) in its preparation phase for new briostatin-1 trials, this metric highlights the absence of current operating profit.